CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025

CNS Pharmaceuticals, Inc.

Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.
Authorized common shares reduced from 300M to 25M; preferred from 5M to 416,667.
No fractional shares; cash in lieu for odd lots.
CUSIP changes to 18978H508; trading symbol CNSP unchanged.
Historical per-share data recast: FY2024 basic loss per share goes from ($38.87) pre-split to ($466.43) post-split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CNS Pharmaceuticals, Inc.: Certificate of Change filed to effect a 1-for-12 reverse stock split, proportionally reducing authorized common stock from 300,000,000 to 25,000,000 and preferred stock from 5,000,000 to 416,667 (effective 2025-07-22).

Change: charter amendment
Effective: 2025-07-22

Exact text from the filing

On July 17, 2025, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-twelve (1-for-12) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-005284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.